<?xml version="1.0"?>
<rss version="2.0">
 <channel>
  <title>StreetInsider.com News Articles</title>
  <link>http://142-54-23-223.fusionmedialtd.com</link>
  <description>Latest StreetInsider.com News Articles</description>
  <language>en-us</language>
  <copyright>Copyright 2026, StreetInsider.com</copyright>
  <managingEditor>rss@streetinsider.com (SI RSS)</managingEditor>
  <webMaster>rss@streetinsider.com (SI RSS)</webMaster>
  <lastBuildDate>Thu, 09 Jul 2026 16:05:00 -0400</lastBuildDate>
  <docs>http://blogs.law.harvard.edu/tech/rss</docs>
  <image>
   <url>http://www.streetinsider.com/images/rss_logo.gif</url>
   <title>StreetInsider.com News Articles</title>
   <link>http://142-54-23-223.fusionmedialtd.com</link>
   <width>143</width>
   <height>28</height>
  </image>
  <skipHours>
   <hour>0</hour>
   <hour>1</hour>
   <hour>2</hour>
   <hour>3</hour>
   <hour>21</hour>
   <hour>22</hour>
   <hour>23</hour>
  </skipHours>
  <skipDays>
   <day>Saturday</day>
   <day>Sunday</day>
  </skipDays>
  <item>
   <title>Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026</title>
   <link>http://www.streetinsider.com/Press+Releases/Fulgent+to+Announce+Second+Quarter+2026+Financial+Results+on+Thursday%2C+July+30%2C+2026/26753198.html</link>
   <description>
&lt;p&gt;    EL MONTE, Calif.--(BUSINESS WIRE)--
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2026 financial results after the market closes on Thursday, July 30, 2026. Management will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questions.

&lt;/p&gt;&lt;p&gt;
The call may be accessed through a live audio webcast on the Investor Relations section of the Company’s website, &lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=http%3A%2F%2Fir.fulgentgenetics.com&amp;amp;esheet=54568091&amp;amp;newsitemid=20260709923437&amp;amp;lan=en-US&amp;amp;anchor=http%3A%2F%2Fir.fulgentgenetics.com&amp;amp;index=1&amp;amp;md5=8153d5de1d21cc4e395a20a4e7e51983&quot;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Fulgent+to+Announce+Second+Quarter+2026+Financial+Results+on+Thursday%2C+July+30%2C+2026/26753198.html</guid>
   <pubDate>Thu, 09 Jul 2026 16:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">FLGT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.30099225</category>
   	  </item>
  <item>
   <title>Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026</title>
   <link>http://www.streetinsider.com/Press+Releases/Fulgent+to+Announce+Second+Quarter+2026+Financial+Results+on+Thursday%2C+July+30%2C+2026/26753198.html</link>
   <description>
&lt;p&gt;    EL MONTE, Calif.--(BUSINESS WIRE)--
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2026 financial results after the market closes on Thursday, July 30, 2026. Management will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questions.

&lt;/p&gt;&lt;p&gt;
The call may be accessed through a live audio webcast on the Investor Relations section of the Company’s website, &lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=http%3A%2F%2Fir.fulgentgenetics.com&amp;amp;esheet=54568091&amp;amp;newsitemid=20260709923437&amp;amp;lan=en-US&amp;amp;anchor=http%3A%2F%2Fir.fulgentgenetics.com&amp;amp;index=1&amp;amp;md5=8153d5de1d21cc4e395a20a4e7e51983&quot;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Fulgent+to+Announce+Second+Quarter+2026+Financial+Results+on+Thursday%2C+July+30%2C+2026/26753198.html</guid>
   <pubDate>Thu, 09 Jul 2026 16:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">FLGT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.30099225</category>
   	  </item>
  <item>
   <title>Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026</title>
   <link>http://www.streetinsider.com/Business+Wire/Fulgent+to+Announce+Second+Quarter+2026+Financial+Results+on+Thursday%2C+July+30%2C+2026/26753198.html</link>
   <description>
&lt;p&gt;    EL MONTE, Calif.--(BUSINESS WIRE)--
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2026 financial results after the market closes on Thursday, July 30, 2026. Management will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questions.

&lt;/p&gt;&lt;p&gt;
The call may be accessed through a live audio webcast on the Investor Relations section of the Company’s website, &lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=http%3A%2F%2Fir.fulgentgenetics.com&amp;amp;esheet=54568091&amp;amp;newsitemid=20260709923437&amp;amp;lan=en-US&amp;amp;anchor=http%3A%2F%2Fir.fulgentgenetics.com&amp;amp;index=1&amp;amp;md5=8153d5de1d21cc4e395a20a4e7e51983&quot;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Fulgent+to+Announce+Second+Quarter+2026+Financial+Results+on+Thursday%2C+July+30%2C+2026/26753198.html</guid>
   <pubDate>Thu, 09 Jul 2026 16:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">FLGT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.30099225</category>
   	  </item>
  <item>
   <title>Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026</title>
   <link>http://www.streetinsider.com/Business+Wire/Fulgent+to+Announce+Second+Quarter+2026+Financial+Results+on+Thursday%2C+July+30%2C+2026/26753198.html</link>
   <description>
&lt;p&gt;    EL MONTE, Calif.--(BUSINESS WIRE)--
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2026 financial results after the market closes on Thursday, July 30, 2026. Management will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questions.

&lt;/p&gt;&lt;p&gt;
The call may be accessed through a live audio webcast on the Investor Relations section of the Company’s website, &lt;a target=&quot;_blank&quot; rel=&quot;nofollow&quot; href=&quot;https://cts.businesswire.com/ct/CT?id=smartlink&amp;amp;url=http%3A%2F%2Fir.fulgentgenetics.com&amp;amp;esheet=54568091&amp;amp;newsitemid=20260709923437&amp;amp;lan=en-US&amp;amp;anchor=http%3A%2F%2Fir.fulgentgenetics.com&amp;amp;index=1&amp;amp;md5=8153d5de1d21cc4e395a20a4e7e51983&quot;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Fulgent+to+Announce+Second+Quarter+2026+Financial+Results+on+Thursday%2C+July+30%2C+2026/26753198.html</guid>
   <pubDate>Thu, 09 Jul 2026 16:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">FLGT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.30099225</category>
   	  </item>
  <item>
   <title>Form  4          Fulgent Genetics, Inc.    For: Jun 01  Filed by: Kim Paul</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Fulgent+Genetics%2C+Inc.++++For%3A+Jun+01++Filed+by%3A+Kim+Paul/26600473.html</link>
   <description>si-local-file:///var/storage/secattach/20260603/26600473.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Fulgent+Genetics%2C+Inc.++++For%3A+Jun+01++Filed+by%3A+Kim+Paul/26600473.html</guid>
   <pubDate>Wed, 03 Jun 2026 17:30:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">FLGT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.30099225</category>
   	  </item>
  <item>
   <title>Form  4          Fulgent Genetics, Inc.    For: Jun 01  Filed by: Kim Paul</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Fulgent+Genetics%2C+Inc.++++For%3A+Jun+01++Filed+by%3A+Kim+Paul/26600473.html</link>
   <description>si-local-file:///var/storage/secattach/20260603/26600473.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Fulgent+Genetics%2C+Inc.++++For%3A+Jun+01++Filed+by%3A+Kim+Paul/26600473.html</guid>
   <pubDate>Wed, 03 Jun 2026 17:30:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">FLGT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.30099225</category>
   	  </item>
  <item>
   <title>Form  4          Fulgent Genetics, Inc.    For: Jun 02  Filed by: Xie Jian</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Fulgent+Genetics%2C+Inc.++++For%3A+Jun+02++Filed+by%3A+Xie+Jian/26600478.html</link>
   <description>si-local-file:///var/storage/secattach/20260603/26600478.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Fulgent+Genetics%2C+Inc.++++For%3A+Jun+02++Filed+by%3A+Xie+Jian/26600478.html</guid>
   <pubDate>Wed, 03 Jun 2026 17:30:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">FLGT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.30099225</category>
   	  </item>
  <item>
   <title>Form  4          Fulgent Genetics, Inc.    For: Jun 02  Filed by: Xie Jian</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Fulgent+Genetics%2C+Inc.++++For%3A+Jun+02++Filed+by%3A+Xie+Jian/26600478.html</link>
   <description>si-local-file:///var/storage/secattach/20260603/26600478.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Fulgent+Genetics%2C+Inc.++++For%3A+Jun+02++Filed+by%3A+Xie+Jian/26600478.html</guid>
   <pubDate>Wed, 03 Jun 2026 17:30:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">FLGT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.30099225</category>
   	  </item>
  <item>
   <title>Form  4          Fulgent Genetics, Inc.    For: Jun 01  Filed by: Hsieh Ming</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Fulgent+Genetics%2C+Inc.++++For%3A+Jun+01++Filed+by%3A+Hsieh+Ming/26600461.html</link>
   <description>si-local-file:///var/storage/secattach/20260603/26600461.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Fulgent+Genetics%2C+Inc.++++For%3A+Jun+01++Filed+by%3A+Hsieh+Ming/26600461.html</guid>
   <pubDate>Wed, 03 Jun 2026 17:29:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">FLGT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.30099225</category>
   	  </item>
  <item>
   <title>Form  4          Fulgent Genetics, Inc.    For: Jun 01  Filed by: Hsieh Ming</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Fulgent+Genetics%2C+Inc.++++For%3A+Jun+01++Filed+by%3A+Hsieh+Ming/26600461.html</link>
   <description>si-local-file:///var/storage/secattach/20260603/26600461.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Fulgent+Genetics%2C+Inc.++++For%3A+Jun+01++Filed+by%3A+Hsieh+Ming/26600461.html</guid>
   <pubDate>Wed, 03 Jun 2026 17:29:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">FLGT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.30099225</category>
   	  </item>
  <item>
   <title>Form  4          Fulgent Genetics, Inc.    For: Jun 02  Filed by: Gao Hanlin</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Fulgent+Genetics%2C+Inc.++++For%3A+Jun+02++Filed+by%3A+Gao+Hanlin/26600464.html</link>
   <description>si-local-file:///var/storage/secattach/20260603/26600464.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Fulgent+Genetics%2C+Inc.++++For%3A+Jun+02++Filed+by%3A+Gao+Hanlin/26600464.html</guid>
   <pubDate>Wed, 03 Jun 2026 17:29:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">FLGT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.30099225</category>
   	  </item>
  <item>
   <title>Form  4          Fulgent Genetics, Inc.    For: Jun 02  Filed by: Gao Hanlin</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Fulgent+Genetics%2C+Inc.++++For%3A+Jun+02++Filed+by%3A+Gao+Hanlin/26600464.html</link>
   <description>si-local-file:///var/storage/secattach/20260603/26600464.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Fulgent+Genetics%2C+Inc.++++For%3A+Jun+02++Filed+by%3A+Gao+Hanlin/26600464.html</guid>
   <pubDate>Wed, 03 Jun 2026 17:29:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">FLGT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.30099225</category>
   	  </item>
  <item>
   <title>Form  144        Fulgent Genetics, Inc.                 Filed by: Xie Jian</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++144++++++++Fulgent+Genetics%2C+Inc.+++++++++++++++++Filed+by%3A+Xie+Jian/26593997.html</link>
   <description>si-local-file:///var/storage/secattach/20260602/26593997.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++144++++++++Fulgent+Genetics%2C+Inc.+++++++++++++++++Filed+by%3A+Xie+Jian/26593997.html</guid>
   <pubDate>Tue, 02 Jun 2026 20:31:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">FLGT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.30099225</category>
   	  </item>
  <item>
   <title>Form  144        Fulgent Genetics, Inc.                 Filed by: Xie Jian</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++144++++++++Fulgent+Genetics%2C+Inc.+++++++++++++++++Filed+by%3A+Xie+Jian/26593997.html</link>
   <description>si-local-file:///var/storage/secattach/20260602/26593997.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++144++++++++Fulgent+Genetics%2C+Inc.+++++++++++++++++Filed+by%3A+Xie+Jian/26593997.html</guid>
   <pubDate>Tue, 02 Jun 2026 20:31:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">FLGT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.30099225</category>
   	  </item>
  <item>
   <title>Form  8-K        Fulgent Genetics, Inc.    For: Jun 01</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Fulgent+Genetics%2C+Inc.++++For%3A+Jun+01/26586658.html</link>
   <description>si-local-file:///var/storage/secattach/20260602/26586658.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Fulgent+Genetics%2C+Inc.++++For%3A+Jun+01/26586658.html</guid>
   <pubDate>Tue, 02 Jun 2026 06:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">FLGT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.30099225</category>
   	  </item>
  <item>
   <title>Form  8-K        Fulgent Genetics, Inc.    For: Jun 01</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Fulgent+Genetics%2C+Inc.++++For%3A+Jun+01/26586658.html</link>
   <description>si-local-file:///var/storage/secattach/20260602/26586658.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Fulgent+Genetics%2C+Inc.++++For%3A+Jun+01/26586658.html</guid>
   <pubDate>Tue, 02 Jun 2026 06:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">FLGT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.30099225</category>
   	  </item>
  <item>
   <title>Fulgent Presents Updated FID-007 Data at ASCO 2026</title>
   <link>http://www.streetinsider.com/Press+Releases/Fulgent+Presents+Updated+FID-007+Data+at+ASCO+2026/26585525.html</link>
   <description>
&lt;p&gt;    EL MONTE, Calif.--(BUSINESS WIRE)--
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with established laboratory services and therapeutic development businesses, today announced it presented updated data in the Head and Neck Cancer Track during the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting Rapid Oral Abstract Session, scheduled from 4:30 p.m. to 6:00 p.m. CDT in Hall D1 at McCormick Place in Chicago.

&lt;/p&gt;&lt;p&gt;
The abstract, entitled “&lt;i&gt;FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), Abstract #6020&lt;/i&gt;,” will present updated preliminary data from the Company’s</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Fulgent+Presents+Updated+FID-007+Data+at+ASCO+2026/26585525.html</guid>
   <pubDate>Mon, 01 Jun 2026 19:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FLGT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.30099225</category>
   	  </item>
  <item>
   <title>Fulgent Presents Updated FID-007 Data at ASCO 2026</title>
   <link>http://www.streetinsider.com/Press+Releases/Fulgent+Presents+Updated+FID-007+Data+at+ASCO+2026/26585525.html</link>
   <description>
&lt;p&gt;    EL MONTE, Calif.--(BUSINESS WIRE)--
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with established laboratory services and therapeutic development businesses, today announced it presented updated data in the Head and Neck Cancer Track during the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting Rapid Oral Abstract Session, scheduled from 4:30 p.m. to 6:00 p.m. CDT in Hall D1 at McCormick Place in Chicago.

&lt;/p&gt;&lt;p&gt;
The abstract, entitled “&lt;i&gt;FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), Abstract #6020&lt;/i&gt;,” will present updated preliminary data from the Company’s</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Fulgent+Presents+Updated+FID-007+Data+at+ASCO+2026/26585525.html</guid>
   <pubDate>Mon, 01 Jun 2026 19:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FLGT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.30099225</category>
   	  </item>
  <item>
   <title>Fulgent Presents Updated FID-007 Data at ASCO 2026</title>
   <link>http://www.streetinsider.com/Press+Releases/Fulgent+Presents+Updated+FID-007+Data+at+ASCO+2026/26585525.html</link>
   <description>
&lt;p&gt;    EL MONTE, Calif.--(BUSINESS WIRE)--
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with established laboratory services and therapeutic development businesses, today announced it presented updated data in the Head and Neck Cancer Track during the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting Rapid Oral Abstract Session, scheduled from 4:30 p.m. to 6:00 p.m. CDT in Hall D1 at McCormick Place in Chicago.

&lt;/p&gt;&lt;p&gt;
The abstract, entitled “&lt;i&gt;FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), Abstract #6020&lt;/i&gt;,” will present updated preliminary data from the Company’s</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Fulgent+Presents+Updated+FID-007+Data+at+ASCO+2026/26585525.html</guid>
   <pubDate>Mon, 01 Jun 2026 19:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FLGT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.30099225</category>
   	  </item>
  <item>
   <title>Fulgent Presents Updated FID-007 Data at ASCO 2026</title>
   <link>http://www.streetinsider.com/Press+Releases/Fulgent+Presents+Updated+FID-007+Data+at+ASCO+2026/26585525.html</link>
   <description>
&lt;p&gt;    EL MONTE, Calif.--(BUSINESS WIRE)--
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with established laboratory services and therapeutic development businesses, today announced it presented updated data in the Head and Neck Cancer Track during the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting Rapid Oral Abstract Session, scheduled from 4:30 p.m. to 6:00 p.m. CDT in Hall D1 at McCormick Place in Chicago.

&lt;/p&gt;&lt;p&gt;
The abstract, entitled “&lt;i&gt;FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), Abstract #6020&lt;/i&gt;,” will present updated preliminary data from the Company’s</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Fulgent+Presents+Updated+FID-007+Data+at+ASCO+2026/26585525.html</guid>
   <pubDate>Mon, 01 Jun 2026 19:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FLGT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.30099225</category>
   	  </item>
  <item>
   <title>Fulgent Presents Updated FID-007 Data at ASCO 2026</title>
   <link>http://www.streetinsider.com/Business+Wire/Fulgent+Presents+Updated+FID-007+Data+at+ASCO+2026/26585525.html</link>
   <description>
&lt;p&gt;    EL MONTE, Calif.--(BUSINESS WIRE)--
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with established laboratory services and therapeutic development businesses, today announced it presented updated data in the Head and Neck Cancer Track during the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting Rapid Oral Abstract Session, scheduled from 4:30 p.m. to 6:00 p.m. CDT in Hall D1 at McCormick Place in Chicago.

&lt;/p&gt;&lt;p&gt;
The abstract, entitled “&lt;i&gt;FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), Abstract #6020&lt;/i&gt;,” will present updated preliminary data from the Company’s</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Fulgent+Presents+Updated+FID-007+Data+at+ASCO+2026/26585525.html</guid>
   <pubDate>Mon, 01 Jun 2026 19:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FLGT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.30099225</category>
   	  </item>
  <item>
   <title>Fulgent Presents Updated FID-007 Data at ASCO 2026</title>
   <link>http://www.streetinsider.com/Business+Wire/Fulgent+Presents+Updated+FID-007+Data+at+ASCO+2026/26585525.html</link>
   <description>
&lt;p&gt;    EL MONTE, Calif.--(BUSINESS WIRE)--
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with established laboratory services and therapeutic development businesses, today announced it presented updated data in the Head and Neck Cancer Track during the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting Rapid Oral Abstract Session, scheduled from 4:30 p.m. to 6:00 p.m. CDT in Hall D1 at McCormick Place in Chicago.

&lt;/p&gt;&lt;p&gt;
The abstract, entitled “&lt;i&gt;FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), Abstract #6020&lt;/i&gt;,” will present updated preliminary data from the Company’s</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Fulgent+Presents+Updated+FID-007+Data+at+ASCO+2026/26585525.html</guid>
   <pubDate>Mon, 01 Jun 2026 19:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FLGT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.30099225</category>
   	  </item>
  <item>
   <title>Fulgent Presents Updated FID-007 Data at ASCO 2026</title>
   <link>http://www.streetinsider.com/Business+Wire/Fulgent+Presents+Updated+FID-007+Data+at+ASCO+2026/26585525.html</link>
   <description>
&lt;p&gt;    EL MONTE, Calif.--(BUSINESS WIRE)--
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with established laboratory services and therapeutic development businesses, today announced it presented updated data in the Head and Neck Cancer Track during the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting Rapid Oral Abstract Session, scheduled from 4:30 p.m. to 6:00 p.m. CDT in Hall D1 at McCormick Place in Chicago.

&lt;/p&gt;&lt;p&gt;
The abstract, entitled “&lt;i&gt;FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), Abstract #6020&lt;/i&gt;,” will present updated preliminary data from the Company’s</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Fulgent+Presents+Updated+FID-007+Data+at+ASCO+2026/26585525.html</guid>
   <pubDate>Mon, 01 Jun 2026 19:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FLGT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.30099225</category>
   	  </item>
  <item>
   <title>Fulgent Presents Updated FID-007 Data at ASCO 2026</title>
   <link>http://www.streetinsider.com/Business+Wire/Fulgent+Presents+Updated+FID-007+Data+at+ASCO+2026/26585525.html</link>
   <description>
&lt;p&gt;    EL MONTE, Calif.--(BUSINESS WIRE)--
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with established laboratory services and therapeutic development businesses, today announced it presented updated data in the Head and Neck Cancer Track during the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting Rapid Oral Abstract Session, scheduled from 4:30 p.m. to 6:00 p.m. CDT in Hall D1 at McCormick Place in Chicago.

&lt;/p&gt;&lt;p&gt;
The abstract, entitled “&lt;i&gt;FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), Abstract #6020&lt;/i&gt;,” will present updated preliminary data from the Company’s</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Fulgent+Presents+Updated+FID-007+Data+at+ASCO+2026/26585525.html</guid>
   <pubDate>Mon, 01 Jun 2026 19:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FLGT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.30099225</category>
   	  </item>
  <item>
   <title>Form  4          Fulgent Genetics, Inc.    For: May 27  Filed by: Xie Jian</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Fulgent+Genetics%2C+Inc.++++For%3A+May+27++Filed+by%3A+Xie+Jian/26568934.html</link>
   <description>si-local-file:///var/storage/secattach/20260528/26568934.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Fulgent+Genetics%2C+Inc.++++For%3A+May+27++Filed+by%3A+Xie+Jian/26568934.html</guid>
   <pubDate>Thu, 28 May 2026 17:22:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">FLGT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.30099225</category>
   	  </item>
 </channel>
</rss>
